Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.51 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2940941 | 0.84 | FAAH (0.49) | FAAHCXCL8ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL18697277 | 0.84 | FAAH (0.49) | FAAHCXCL8ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL57243 | 0.84 | FAAH (0.49) | FAAHCXCL8ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL29585912 | 0.84 | FAAH (0.49) | FAAHCXCL8ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL143632 | 0.83 | KDM4E (0.46) | ALDH1A1SMN1; SMN2MAPTKDM4EKMT2A | |
| SCHEMBL6966435 | 0.82 | FAAH (0.47) | FAAHCXCL8ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL1323923 | 0.81 | KMT2A (0.63) | FAAHSMN1; SMN2MAPTPARP10MRGPRX4 | |
| SCHEMBL2322496 | 0.80 | PARP10 (0.53) | FAAHCXCL8ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL247351 | 0.80 | PTGS2 (0.57) | FAAHCXCL8ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL1977066 | 0.80 | ALDH1A1 (0.48) | FAAHCXCL8ALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023179324-A1 | ELECTROLYTIC SOLUTION CONTAINING FLUOROBENZENE CARBONATE, AND BATTERY COMPOSED OF ELECTROLYTIC SOLUTION | 香河昆仑新能源材料股份有限公司 | 2023-09-28 | — | — | WO | claimed |
| EP-4227293-A2 | CRYSTALLINE FORMS OF 1-(ACYLOXY)-ALKYL CARBAMATE DRUG CONJUGATES OF NAPROXEN AND PREGABALIN | Xgene Pharmaceutical Inc (KY) | 2023-08-16 | — | — | EP | claimed |
| EP-2951299-A1 | CYSTATHIONINE BETA-SYNTHASE ENZYME FOR TREATMENT OF HOMOCYSTINURIA | The Regents of The University of Colorado, A Body Corporate (US) | 2015-12-09 | — | — | EP | claimed |
| EP-2154138-B1 | NOVEL COMPOUNDS FOR TREATMENT OF PSYCHOTIC DISORDERS, PREPARATION METHODS AND USES THEREOF | LI YOUXIN (CN) | 2015-08-19 | — | — | EP | claimed |
| WO-2014120770-A1 | CYSTATHIONINE BETA-SYNTHASE ENZYME FOR TREATMENT OF HOMOCYSTINURIA | THE REGENTS OF UNIVERSITY OF COLORADO (US) | 2014-08-07 | — | — | WO | claimed |
| EP-1572728-B1 | POLYMER CONJUGATES WITH DECREASED ANTIGENICITY, METHODS OF PREPARATION AND USES THEREOF | MOUNTAIN VIEW PHARMACEUTICALS (US) | 2014-06-25 | — | — | EP | claimed |
| US-20120114742-A1 | Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof | MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | claimed |
| US-8129330-B2 | Complex of polyoxyethylene glycol with active material | MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) | 2012-03-06 | — | — | US | claimed |
| JP-2006510601-A | — | — | 2006-03-30 | — | — | JP | claimed |
| EP-1572728-A2 | POLYMER CONJUGATES WITH DECREASED ANTIGENICITY, METHODS OF PREPARATION AND USES THEREOF | Mountain View Pharmaceuticals, Inc. (US) | 2005-09-14 | — | — | EP | claimed |
| EP-1421175-A4 | POLYMER STABILIZED PROTEINASES | MOUNTAIN VIEW PHARMACEUTICALS (US) | 2004-12-08 | — | — | EP | claimed |
| EP-1421175-A2 | POLYMER STABILIZED PROTEINASES | Mountain View Pharmaceuticals, Inc. (US) | 2004-05-26 | — | — | EP | claimed |
| WO-2004030617-A2 | POLYMER CONJUGATES WITH DECREASED ANTIGENICITY, METHODS OF PREPARATION AND USES THEREOF | MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) | 2004-04-15 | — | — | WO | claimed |
| US-20040062746-A1 | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof | MOUNTAIN VIEW PHARMACEUTICALS, INC. | 2004-04-01 | — | — | US | claimed |
| US-20040062748-A1 | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof | MOUNTAIN VIEW PHARMACEUTICALS, INC. | 2004-04-01 | — | — | US | claimed |
| US-20030012777-A1 | Polymer conjugates of proteinases | MOUNTAIN VIEW PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | claimed |
| WO-2003002716-A2 | POLYMER STABILIZED PROTEINASES | MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) | 2003-01-09 | — | — | WO | claimed |
| EP-4406536-A2 | CYSTATHIONINE BETA-SYNTHASE ENZYME FOR TREATMENT OF HOMOCYSTINURIA | The Regents of The University of Colorado, A Body Corporate (US) | 2024-07-31 | — | — | EP | disclosed |
| EP-0180188-B1 | A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040062748-A1 | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof | CD14, HLA-C, HLA-A | FAAH 1966/4885CXCL8 943/4885ALDH1A1 3287/4885 |
| US-20040062746-A1 | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof | CD14, HLA-C, HLA-A | FAAH 1966/4885CXCL8 943/4885ALDH1A1 3287/4885 |
| US-20120114742-A1 | Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof | CD14, HLA-C, HLA-A | FAAH 1966/4885CXCL8 943/4885ALDH1A1 3287/4885 |
| US-20030012777-A1 | Polymer conjugates of proteinases | PRNP, PRSS3, PRSS1 | FAAH 3421/4885CXCL8 3361/4885ALDH1A1 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.